Spironolactone Ceva

RSS

Withdrawn

This medicine's authorisation has been withdrawn

spironolactone
MedicineVeterinaryWithdrawn

Icelandic is available via eTranslation, the European Commission's machine translation service.

Translate to Icelandic | Important information about machine translation

  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

The marketing authorisation for this product has been withdrawn due to the application of the sunset clause.

български (BG) (332.91 KB - PDF)

Skoða

español (ES) (288.28 KB - PDF)

Skoða

čeština (CS) (322.23 KB - PDF)

Skoða

dansk (DA) (287.53 KB - PDF)

Skoða

Deutsch (DE) (289.53 KB - PDF)

Skoða

eesti (ET) (276.29 KB - PDF)

Skoða

ελληνικά (EL) (335.21 KB - PDF)

Skoða

français (FR) (289.25 KB - PDF)

Skoða

hrvatski (HR) (307.68 KB - PDF)

Skoða

latviešu (LV) (334.28 KB - PDF)

Skoða

Malti (MT) (324.47 KB - PDF)

Skoða

Nederlands (NL) (287.82 KB - PDF)

Skoða

polski (PL) (380.69 KB - PDF)

Skoða

português (PT) (288.12 KB - PDF)

Skoða

română (RO) (482.45 KB - PDF)

Skoða

slovenčina (SK) (324.97 KB - PDF)

Skoða

slovenščina (SL) (318.42 KB - PDF)

Skoða

suomi (FI) (285.73 KB - PDF)

Skoða

svenska (SV) (287.15 KB - PDF)

Skoða

Product information

български (BG) (936.84 KB - PDF)

Skoða

español (ES) (457.64 KB - PDF)

Skoða

čeština (CS) (695.23 KB - PDF)

Skoða

dansk (DA) (443.55 KB - PDF)

Skoða

Deutsch (DE) (456.17 KB - PDF)

Skoða

eesti (ET) (460.88 KB - PDF)

Skoða

ελληνικά (EL) (957.24 KB - PDF)

Skoða

français (FR) (383.63 KB - PDF)

Skoða

hrvatski (HR) (504.46 KB - PDF)

Skoða

italiano (IT) (614.01 KB - PDF)

Skoða

latviešu (LV) (750.12 KB - PDF)

Skoða

lietuvių (LT) (673.01 KB - PDF)

Skoða

magyar (HU) (1.07 MB - PDF)

Skoða

Malti (MT) (774.79 KB - PDF)

Skoða

Nederlands (NL) (445.92 KB - PDF)

Skoða

polski (PL) (1.09 MB - PDF)

Skoða

português (PT) (456.69 KB - PDF)

Skoða

română (RO) (807.04 KB - PDF)

Skoða

slovenčina (SK) (711.68 KB - PDF)

Skoða

slovenščina (SL) (702.28 KB - PDF)

Skoða

suomi (FI) (456.54 KB - PDF)

Skoða

svenska (SV) (441.7 KB - PDF)

Skoða

Íslenska (IS) (622.5 KB - PDF)

Skoða

norsk (NO) (656.3 KB - PDF)

Skoða
Latest procedure affecting product information:IAIN/0014
31/10/2012

български (BG) (299.51 KB - PDF)

Skoða

español (ES) (219.22 KB - PDF)

Skoða

čeština (CS) (262.67 KB - PDF)

Skoða

dansk (DA) (227.42 KB - PDF)

Skoða

Deutsch (DE) (218.75 KB - PDF)

Skoða

eesti (ET) (221.16 KB - PDF)

Skoða

ελληνικά (EL) (268.37 KB - PDF)

Skoða

français (FR) (221.14 KB - PDF)

Skoða

hrvatski (HR) (227.55 KB - PDF)

Skoða

italiano (IT) (191.92 KB - PDF)

Skoða

latviešu (LV) (256.74 KB - PDF)

Skoða

lietuvių (LT) (210.34 KB - PDF)

Skoða

magyar (HU) (210.45 KB - PDF)

Skoða

Malti (MT) (250.85 KB - PDF)

Skoða

Nederlands (NL) (228.06 KB - PDF)

Skoða

polski (PL) (245.92 KB - PDF)

Skoða

português (PT) (231.37 KB - PDF)

Skoða

română (RO) (434.62 KB - PDF)

Skoða

slovenčina (SK) (253.67 KB - PDF)

Skoða

slovenščina (SL) (237.31 KB - PDF)

Skoða

suomi (FI) (204.11 KB - PDF)

Skoða

svenska (SV) (218.51 KB - PDF)

Skoða

Íslenska (IS) (185.95 KB - PDF)

Skoða

norsk (NO) (222.67 KB - PDF)

Skoða

Product details

Name of medicine
Spironolactone Ceva
Active substance
spironolactone
International non-proprietary name (INN) or common name
spironolactone
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) code
QC03DA01

Pharmacotherapeutic group

Diuretics

Therapeutic indication

For use in combination with standard therapy (including diuretic support, where necessary) for the treatment of congestive heart failure caused by valvular regurgitation in dogs.

Authorisation details

EMA product number
EMEA/V/C/000105
Marketing authorisation holder
Ceva Santé Animale

10 avenue de la Ballastière
33500 Libourne
France

Opinion adopted
17/04/2007
Marketing authorisation issued
20/06/2007
Revision
7

Assessment history

This page was last updated on

Share this page